摘要
用差异ＰＣＲ方法检测了１３１例乳腺癌Ｃ－ｅｒｂＢ－２基因扩增，免疫组化法检测了１３１例乳腺癌Ｃ－ｅｒｂＢ－２和Ｃａｔｈｅｐｓｉｎ－Ｄ表达，并对其对乳腺癌的预后影响进行评价。Ｃ－ｅｒｂＢ２基因扩增阳性率为２９．０１％，与临床分期、病理类型、组织学分级和淋巴结转移状况无明显相关，与Ｃ－ｅｒｂＢ－２蛋白表达虽不完全吻合但呈高度相关。Ｃ－ｅｒｂＢ－２表达阳性率为３２．０６％，与临床分期、病理类型、组织学分级、淋巴结转移状况及瘤体大小未见明显相关，转移灶和原发灶表达一致。Ｃａｔｈｅｐ－ｓｉｎ－Ｄ表达阳性率为３２．０６％，与淋巴瘤结转移状况、Ｃ－ｅｒｂＢ－２表达及病理类型明显相关。单因素分析表明Ｃ－ｅｒｂＢ－２基因扩增、Ｃ－ｅｒｂＢ－２表达及Ｃａｔｈ－Ｄ表达对乳腺癌术后生存及无瘤生存影响显著，Ｃｏｘ模型多因素回归分析表明Ｃ－ｅｒｂＢ－２表达是乳腺癌一独立预后指标。联合应用Ｃ－ｅｒｂＢ－２和Ｃａｔｈ－Ｄ表达检测更有助于早期病例和淋巴结转移阴性病例中高危患者的筛选。
C-erbB-2 gene amplification、C-erbB-2 and Cath-Dexpressions were examined in 131 cases of primary breast cancer via differential PCR and immunohistochemic techniques Their Prognostic effects were evaluated.The positive rate of C-erbB-2 amplification was 29 01%,no significant association was found between C-erbB-2 amplification with clinical stage、 pathologic type、histological grade or lymph node status;though not always parallel to C-erbB-2 expression,C-erbB-2 amplifications markedly correlated to the protein expressions.42 out of 131 cases were C-erbB-2 positive staining,no significant correlations had been found between C-erbB-2 expression and stage、tumoursize、grade、type or lymph node status. Positive rate of Cath-Dexpressions was 32.06%,Cath-D expressions were strongly associated with C-erb B-2 expressions、lymph node status as well as pathological types.Univariate analysis showed all of C-erb B-2 amplification、C-erb B-2 expression and Cath-D expression would predict poor prognosis,Cox model mutivariates regression analysis showed C-erb B-2 expression an independent prognostic indicator.Combined detections of C-erb B-2 and Cath-Dxpressions are of significant importance for high risk patients screening from early stage or lymph node negative breast carcinomas.
